[Benign prostatic syndrome. 3-step plan for the treatment].
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017292:Doxazosin / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D018120:Finasteride / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D012307:Risk Factors; D014463:Ultrasonography
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D010919:Placebos; D018120:Finasteride; D017430:Prostate-Specific Antigen; D017292:Doxazosin